Diagnostic Accuracy of Brain-derived Neurotrophic Factor and Nitric oxide in Patients with Schizophrenia. A pilot study/ Dijagnostička tačnost moždanog neurotrofičkog faktora i azot-monoksida kod obolelih od shizofrenije.Pilot studija

Abstract

SummaryBackgroundBrain-derived neurotrophic factor (BDNF) and nitric oxide (NO) play multiple roles in the developing and adult CNS. Since BDNF and NO metabolisms are dysregulated in schizophrenia, we measured these markers simultaneously in the blood of schizophrenics and assessed their diagnostic accuracy.MethodsThirty-eight patients with schizophrenia classified according to demographic characteristics, symptomatologyand therapy and 39 age- and gender-matched healthy controls were enrolled. BDNF was determined by the ELISA technique while the concentration of nitrite/nitrate (MJX-TeXAtom-ORDNO2−MJX-TeXAtom-ORD/MJX-TeXAtom-ORDNO3−) was measured by the colorimetric method.ResultsSerum BDNF levels were significantly lower (20.38±3.73 ng/mL, P = 1.339E-05), whilst plasma MJX-TeXAtom-ORDNO2−MJX-TeXAtom-ORD/MJX-TeXAtom-ORDNO3− concentrations were significantly higher (84.3 (72–121) μmol/L, P=4.357E-08) in patients with schizophrenia than in healthy controls (25.65±4.32 ng/mL; 60.9 (50–76) μmol/L, respectively). The lowest value of BDNF (18.14±3.26 ng/mL) and the highest MJX-TeXAtom-ORDNO2−MJX-TeXAtom-ORD/MJX-TeXAtom-ORDNO3− concentration (115.3 (80–138) μmol/L) were found in patients treated with second-generation antipsychotics (SGA). The patients diseased before the age of 24 and the patients suffering for up to one year had significantly lower serum BDNF levels than those diseased after the age of 24 and the patients who were ill longer than one year. Both BDNF and MJX-TeXAtom-ORDNO2−MJX-TeXAtom-ORD/MJX-TeXAtom-ORDNO3− showed good diagnostic accuracy, but BDNF had better ROC curve characteristics, especially in patients with negative symptomatology.ConclusionsBDNF and nitrite/nitrate showed inverse changes in schizophrenic patients. The most pronounced changes were found in patients treated with second-generation antipsychotics. Although BDNF is not specific of schizophrenia, it may be a clinically useful biomarker for the diagnosis of patients expressing predominantly negative symptoms.

The Relation of Brain-Derived Neurotropic Factor (BDNF) Serum Level to Sub-Domain Cognitive Functions of Indonesian Schizophrenia Patients Measured by MoCA-Ina

“…The meta-analysis of all studies was collected to confirm the decreasing of BDNF levels of schizophrenic patients to be compared to the control group, however, no significant results were found in no medication cases. A study conducted by Djordjevi et al, [23] in 2016 found that the BDNF serum levels were significantly lower (20.38 ± 3.73 ng/mL, P = 1.339 E-05), whereas the NO2 concentration of plasma was significantly higher (84.3 (72-121) mmol/L, P = 4.357E-08) than those who were classified as control healthy (25.65 ± 4.32 ng/mL; 60.9 (50-76) mmol/ L respectively) [23]. Based on the assessment of cognitive function for the eight domains to the schizophrenic patients, it was found positive correlation with medium power (r = 0.4 -< 0.6) to the visuospatial (r = 0.402), attention (r = 0.437), and memory (r = 0.413).…”